ArticleIndian journal of ophthalmology2026
Ocular surface reconstruction using collagen matrix implant in cases of moderate to severe symblepharon: A pilot study.
Article in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the safety and efficacy of a collagen matrix implant (CMI) as an adjunct in ocular surface reconstruction for moderate to severe post-chemical injury symblepharon.
methodsThis prospective interventional pilot study included ten eyes of nine patients (all male, mean age 17.90 ± 9.48 years) with moderate (n = 4) or severe (n = 6) symblepharon secondary to chemical injury. All patients underwent symblepharon lysis, followed by ocular surface reconstruction using mucous membrane graft and amniotic membrane graft, with the additional placement of a CMI secured with 6-0 vicryl sutures. A symblepharon ring was placed postoperatively for 6-8 weeks. All patients were followed for at least 6 months. Surgical success was defined as ≥30% forniceal depth (FD) correction at 3 months, categorized as excellent (75 - 100%), good (60 to <75%), or poor (30 to <60%). Recurrence was defined as a >2 mm decrease in FD from the 3-month value. Statistical analysis was performed using SPSS v23.
resultsAll nine patients completed 6 months of follow-up. There was no case of failure or recurrence. The mean percent depth correction at 3 months was 78.32% in the upper eyelid and 74.47% in the lower eyelid. The mean upper middle FD increased significantly from 4.40 mm preoperatively to 12.20 mm at 3 months, stabilizing at 11.40 mm at 6 months. Similarly, the mean lower middle FD improved from 2.42 mm to 7.57 mm at 3 months, maintaining 7.28 mm at 6 months (Friedman test: χ2 = 10.78, P = 0.00455). Anatomical outcomes were excellent in 8 eyes, good in 1 eye, and poor in 1 eye. Two patients showed significant visual acuity improvement. One patient developed postoperative orbital cellulitis, and three had pyogenic granuloma (not implant-related). There were no cases of implant extrusion.
conclusionThe collagen matrix implant appears to be a safe and effective adjunct for ocular surface reconstruction in moderate to severe post-chemical injury symblepharon, demonstrating encouraging short-term anatomical outcomes with no recurrences at 6 months. Further studies with longer follow-up are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.